FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:802-803 September 21, 1995 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Cortelazzo, S. Related Article by Clark, C. M.

To the Editor: Although the study of Cortelazzo and colleagues (April 27 issue)¹ was not designed to assess the role of antiplatelet drugs in preventing vascular thrombotic complications of essential thrombocythemia, the authors note that the relative risk of thrombosis was not significantly reduced by treatment with these drugs. Because 70 percent of the hydroxyurea group and 69 percent of the control group received antiplatelet drugs (aspirin and ticlopidine), the lack of reduction in risk with these drugs merely reflects adequate randomization rather than the lack of a favorable effect of antiplatelet drugs on the incidence of thrombosis. In several . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.